Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: a UK National Cohort Study

• Published in: Europace (London, England) Vol. 23; no. 3; pp. 400 - 408
• Main Authors: Norrish, Gabrielle, Chubb, Henry, Field, Ella, McLeod, Karen, Ilina, Maria, Spentzou, Georgia, Till, Jan, Daubeney, Piers E F, Stuart, Alan Graham, Matthews, Jane, Hares, Dominic, Brown, Elspeth, Linter, Katie, Bhole, Vinay, Pillai, Krishnakumar, Bowes, Michael, Jones, Caroline B, Uzun, Orhan, Wong, Amos, Yue, Arthur, Sadagopan, Shankar, Bharucha, Tara, Yap, Norah, Rosenthal, Eric, Mathur, Sujeev, Adwani, Satish, Reinhardt, Zdenka, Mangat, Jasveer, Kaski, Juan Pablo
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 08.03.2021
• Subjects: Adolescent; Cardiomyopathy, Hypertrophic - diagnosis; Cardiomyopathy, Hypertrophic - therapy; Child; Clinical Research; Cohort Studies; Death, Sudden, Cardiac - epidemiology; Death, Sudden, Cardiac - prevention & control; Defibrillators, Implantable; Humans; Retrospective Studies; Risk Factors; Treatment Outcome; United Kingdom; United Kingdom; Hypertrophic cardiomyopathy; Programming; Implantable cardioverter-defibrillator; Childhood
• ISSN: 1099-5129; 1532-2092; 1532-2092
• DOI: 10.1093/europace/euaa307

Abstract Aims Sudden cardiac death (SCD) is the most common mode of death in paediatric hypertrophic cardiomyopathy (HCM). This study describes the implant and programming strategies with clinical outcomes following implantable cardioverter-defibrillator (ICD) insertion in a well-characterized national paediatric HCM cohort. Methods and results Data from 90 patients undergoing ICD insertion at a median age 13 (±3.5) for primary (n = 67, 74%) or secondary prevention (n = 23, 26%) were collected from a retrospective, longitudinal multi-centre cohort of children (<16 years) with HCM from the UK. Seventy-six (84%) had an endovascular system [14 (18%) dual coil], 3 (3%) epicardial, and 11 (12%) subcutaneous system. Defibrillation threshold (DFT) testing was performed at implant in 68 (76%). Inadequate DFT in four led to implant adjustment in three patients. Over a median follow-up of 54 months (interquartile range 28–111), 25 (28%) patients had 53 appropriate therapies [ICD shock n = 45, anti-tachycardia pacing (ATP) n = 8], incidence rate 4.7 per 100 patient years (95% CI 2.9–7.6). Eight inappropriate therapies occurred in 7 (8%) patients (ICD shock n = 4, ATP n = 4), incidence rate 1.1/100 patient years (95% CI 0.4–2.5). Three patients (3%) died following arrhythmic events, despite a functioning device. Other device complications were seen in 28 patients (31%), including lead-related complications (n = 15) and infection (n = 10). No clinical, device, or programming characteristics predicted time to inappropriate therapy or lead complication. Conclusion In a large national cohort of paediatric HCM patients with an ICD, device and programming strategies varied widely. No particular strategy was associated with inappropriate therapies, missed/delayed therapies, or lead complications.